Alnylam Pharmaceuticals, Inc. announced the appointment of Peter Kellogg to its Board of Directors. Mr. Kellogg is an accomplished industry executive with extensive global financial and strategic management experience. Throughout his career, Mr. Kellogg played a critical role at leading biopharmaceutical companies with responsibility for core financial functions, including investor relations, corporate strategy, business development and alliance management.

He most recently served as EVP, Chief Corporate Strategy Officer and had previously served as EVP, Chief Financial Officer at Celgene Corporation where he was instrumental in the consistent, year-over-year delivery of strong operating results up through the Company's acquisition in 2019 by Bristol Myers Squibb. Prior to Celgene, Mr. Kellogg held the position of Chief Financial Officer at Merck & Co., Biogen Inc., and Frito Lay International, a division of PepsiCo, Inc. Currently, Mr. Kellogg serves as a member of the Board of Directors of Idorsia Ltd.